Cerebrovascular diseases
-
Cerebrovascular diseases · Jan 2009
ReviewHigh blood pressure in acute ischaemic stroke--broadening therapeutic horizons.
High blood pressure (BP) is present in 80% of patients with acute ischaemic stroke and is independently associated with poor outcome. Although this epidemiology suggests that BP should be lowered acutely, concerns about dysfunctional cerebral autoregulation suggest otherwise. Several small randomised trials have assessed cerebral blood flow with various antihypertensive classes and agents in acute ischaemic stroke. ⋯ Two larger trials reported that glucose-potassium-insulin therapy (GIST) or magnesium (IMAGES) lowered BP but had no effect on functional outcome. The INTERACT pilot trial studied patients with intracerebral haemorrhage and found that an intensive BP-lowering regime non-significantly reduced haematoma expansion. There are four large ongoing trials examining whether to continue or stop pre-stroke antihypertensive therapy (COSSACS, ENOS) or lower BP in acute stroke (ENOS, SCAST) or haemorrhage (INTERACT 2).
-
Cerebrovascular diseases · Jan 2009
ReviewGenetic association studies in ischaemic stroke: replication failure and prospects.
Although hundreds of genetic association studies of ischaemic stroke have been published, the failure to replicate associations has led to scepticism about their findings. Possible explanations for this failure are: (1) a false-positive association in the initial study; (2) a false-negative association in a replication study; (3) methodological differences (e.g. study populations or study designs). We review underlying causes for replication failure, such as small sample size, multiple testing and publication bias, and methods to deal with these problems. We also make suggestions about the design of genetic association studies in ischaemic stroke with regard to stroke subtype classification, candidate pathways, subgroups, intermediate phenotypes and potential clinical impact.
-
Cerebrovascular diseases · Jan 2009
ReviewRelevance of neuroimaging in the evaluation of cerebral ischemia.
The rapid development of neuroimaging techniques has provided us with a wide range of tools for the assessment of patients who may have experienced cerebrovascular events. Each of these technologies provides specific and potentially informative insights. For clinical practice, however, we always have to tailor our diagnostic approach according to a maximum benefit/minimal burden and cost ratio. ⋯ For patients in the postacute phase of acute ischemic stroke, neuroimaging should contribute a maximum of information to the clarification of stroke etiology to allow for specific secondary prevention. Patients with transient ischemic attacks appear to represent yet another distinct group of patients who can benefit greatly from a rapid and comprehensive neuroimaging evaluation, as this allows identification of individuals at a specifically high risk for a subsequent stroke. Using these categories, the relevance of respective neuroimaging tools can be substantiated by a large body of evidence.
-
Cerebrovascular diseases · Jan 2009
ReviewOld and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke.
Vitamin K antagonists are the only oral anticoagulants available and are considered as well-established treatment to prevent a first stroke or a recurrent stroke in patients with atrial fibrillation. The difficulties in the routine management of these patients cause an underuse of vitamin K antagonists. For long-term use, there is a need for safer and more effective oral anticoagulants that do not require routine monitoring of coagulation. ⋯ Direct thrombin inhibitors include ximelagatran and dabigatran etexilate. Although ximelagatran was withdrawn early because of liver toxicity, it provided convincing evidence that new oral anticoagulants have the potential to replace warfarin. However, even if these new drugs prove superior to dose-adjusted warfarin, their benefits must be substantial (retaining high efficacy with added safety and convenience) to offset their increased cost.
-
The lack of physicians with specialty stroke training represents a significant challenge to the future of stroke. This deficit limits both quality stroke care and clinical research initiatives. ⋯ Greater diffusion and long-term sustainability of telestroke systems will be dependent upon improvements in patient and hospital reimbursement for acute stroke and telestroke care.